紫杉醇及蒽环类药物联合化疗治疗晚期乳腺癌的临床观察

目的探讨紫杉醇联合蒽环类药物±CTX方案与CAF方案治疗晚期乳腺癌的近期临床疗效和不良反应。方法以紫杉醇联合蒽环类药物±CTX方案为观察组,CAF方案为对照组。结果观察组有效率为72.7%（16/22）,对照组为53.8%（14/26）,观察组优于对照组,但无显著性差异（P〉0.05）。年龄,月经状况,ER、PR,基因表达,临床分期,远处转移等因素,对近期疗效无显著影响（P〉0.05）。不良反应以白细胞减少为主,观察组Ⅲ-Ⅳ度发生率为59.1%,对照组为11.5%,两组比较有显著性差异（P〈0.01）,其他与化疗相关的不良反应程度均较轻,可耐受。结论对于晚期乳腺癌初用化疗者,CAF组与观察组相比疗效无显著差异且不良反应较轻,临床更具优势,值得临床广泛应用。

Comparative Study of the Combined Chemotherapy with Paclitaxel or Antracycline for Advanced Breast Cancer

Objective To study the short-term efficacy and toxicities of combined paclitaxel plus antracycline ± CTX and CAF treatment for advanced breast cancer. Methods Patients treated with paclitaxel plus antraeycline ± CTX were included in the study group, and patients treated with the CAF were included in the control group. Results The response rate was 72.7 % （16/22） for the study group, and 53.8% （14/26） for the control group, with no significant differences （ P 〉 0. 05 ）. Age, menstruation status, ER, PR, gene expression, clinical TNM stage and distant metastases had no significant correlations with the shortteim clinical efficacy （P 〉0.05）. The major toxicity was leucopenia,with 59.1% and 11.5% patients having III-1V leucopenia in the study and control group, respectively. This difference was statistically significant （ P 〈 0.01 ）. Other chemotherapy-related toxicities were mild and tolerable. Conclusion CAF chemotherapy has the same efficacy as the paclitaxel plus antracyeline ± CTX regime, but with less toxicities,in the treatment of patients with advanced breast cancer.